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Abstract: Chemokines interact with chemokine receptors in a promiscuous network, such that
each receptor can be activated by multiple chemokines. Moreover, different chemokines have been
reported to preferentially activate different signalling pathways via the same receptor, a phenomenon
known as biased agonism. The human CC chemokine receptors (CCRs) CCR4, CCR7 and CCR10
play important roles in T cell trafficking and have been reported to display biased agonism. To
systematically characterize these effects, we analysed G protein- and β-arrestin-mediated signal
transduction resulting from stimulation of these receptors by each of their cognate chemokine ligands
within the same cellular background. Although the chemokines did not elicit ligand-biased agonism,
the three receptors exhibited different arrays of signaling outcomes. Stimulation of CCR4 by either CC
chemokine ligand 17 (CCL17) or CCL22 induced β-arrestin recruitment but not G protein-mediated
signaling, suggesting that CCR4 has the potential to act as a scavenger receptor. At CCR7, both CCL19
and CCL21 stimulated G protein signaling and β-arrestin recruitment, with CCL19 consistently
displaying higher potency. At CCR10, CCL27 and CCL28(4-108) stimulated both G protein signaling
and β-arrestin recruitment, whereas CCL28(1-108) was inactive, suggesting that CCL28(4-108) is the
biologically relevant form of this chemokine. These comparisons emphasize the intrinsic abilities of
different receptors to couple with different downstream signaling pathways. Comparison of these
results with previous studies indicates that differential agonism at these receptors may be highly
dependent on the cellular context.
Keywords: chemokine; chemokine receptor; CCR4; CCR7; CCR10; GPCR; signaling pathways;
partial agonism; biased agonism
1. Introduction
Chemokines (chemotactic cytokines) and their receptors are the key regulators of
leukocyte recruitment in both normal immune function and numerous inflammatory
diseases [1,2]. Chemokine receptors are expressed on different types of leukocytes and
signal in response to chemokine binding, giving rise to regulation of leukocyte adhesion and
chemotaxis to sites of high chemokine expression. The chemokine ligands and chemokine
receptors interact in a complex network, such that most chemokines activate multiple
receptors and most receptors respond to multiple chemokines. In humans, there are ~43
chemokines and ~19 receptors, which belong to the family of G protein-coupled receptors
(GPCRs) that signal via heterotrimeric G proteins and non-G protein effectors, such as
β-arrestins. Typically, G protein activation via chemokine receptors promotes chemotaxis
of the receptor-expressing cells. In contrast, several “decoy” chemokine receptors have
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been identified that are not coupled to G proteins but still interact with β-arrestins, leading
to internalization of the chemokine receptor-chemokine ligand complex (thereby acting as
chemokine sinks) [3].
In some cases, different chemokines can activate the same receptor but elicit distinct
signaling responses. Such differences are classified as biased agonism if the ligands differ
in their relative efficiencies of signaling via two alternative pathways, e.g., G protein
versus β-arrestin pathways, or pathways mediated by different G protein subtypes. Biased
agonism has been reported for several chemokine receptors, including CCR1, CCR2, CCR4,
CCR5, CCR7, CCR10, CXCR2 and CXCR3 [4–9]. Biased agonism is distinct from differences
in intrinsic efficacy (or partial agonism), which applies to ligands that activate the same
pathways but differ in the relative magnitude of the signaling outcomes. For example, we
have previously characterized partial agonism at the chemokine receptor CCR2 [10].
Among the chemokine receptors previously reported to exhibit biased agonism are
CCR4, CCR7 and CCR10, all of which play key roles in trafficking of T cells, thus con-
tributing to normal T cell selection, immune responses to viral infection, and/or allergic or
auto-immune reactions. Each of these receptors has two cognate chemokine ligands [1].
CCR4 activation by CCL17 and CCL22 is primarily thought to regulate the migration of
T helper type 2 (Th2) cells during the process of T cell selection as well as during allergic
responses (e.g., asthma and atopic dermatitis) but may also be involved in recruitment
of regulatory T cells and certain subsets of monocytes and dendritic cells (DCs) [11,12].
CCR7 is expressed on various types of T cells, B cells and DCs that migrate to (or within)
lymphoid organs, in which the two CCR7 ligands, CCL19 and CCL21, are expressed [13].
CCR10 is expressed on both T and B cells. Activation of CCR10 by CCL27 promotes the
recruitment of T lymphocytes to the skin, whereas CCR10 activation by CCL28 stimulates
trafficking of immunoglobulin A antibody-secreting plasma cells (B lymphocytes) to mucosal
tissues, including intestines, lung, nasal cavity, uterus and lactating mammary gland [14].
A number of previous studies have investigated the possibility that cognate chemokines
differentially activate CCR4, CCR7 and CCR10, with potential implications for regulation
of lymphocyte trafficking and selection. In the case of CCR4, CCL22 was observed to
be more effective than CCL17 at inducing receptor internalization [15,16] and activation
by the two ligands was affected differently by receptor mutations or inhibitory antibod-
ies [17]. Similarly, for CCR7, several studies have found that CCL19 was more effective
than CCL21 at inducing receptor internalization and β-arrestin recruitment [7–9,18–21].
However, these studies came to different conclusions regarding whether the two ligands
stimulate equivalent G protein-mediated responses via CCR7 [7–9,21]. In the only study
investigating differential agonism at CCR10, Rajagopal et al. [4] reported that both CCL27
and CCL28 effectively stimulated G protein-mediated signaling, whereas only CCL27 was
able to simulate β-arrestin recruitment. Considering the apparent importance of differential
agonism at these chemokine receptors in regulation of immune cell function, we were
interested in identifying the molecular features of both the chemokines and receptors that
contribute to these differences in receptor activation. As a prelude to such studies, we
undertook a systematic evaluation of differential activation of CCR4, CCR7 and CCR10
by their cognate chemokine ligands. Herein, we report our findings and discuss both
similarities and differences amongst these receptors and compared to previous reports.
2. Results
2.1. Cognate Chemokines Stimulate β-Arrestin Recruitment at CCR4, CCR7 and CCR10
Activation of chemokine receptors typically induces G protein receptor kinase (GRK)-
mediated phosphorylation of the receptor C-terminal region and recruitment of β-arrestins
to the phosphorylated receptor, leading to receptor internalization [22]. To detect β-arrestin
recruitment to CCR4, CCR7 and CCR10, we used Chinese hamster ovary (CHO) cells
transiently transfected to express each receptor and β-arrestin2, tagged with a biolumi-
nescence resonance energy transfer (BRET) donor and acceptor, respectively (Figure 1a).
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Treatment of these cells with cognate chemokines of the expressed receptors stimulated
concentration-dependent β-arrestin2 recruitment (Figure 1b–d).
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Figure 1. Chemokine ligands differentially stimulate β-arrestin recruitment to CCR4, CCR7 and CCR10. (a) The principle
of the BRET-based β-arresti recruitment assay. The Renilla luciferase (RLuc8) is fused at the C-termini of the receptors
and the yellow fluorescent protein (YFP) tagged at the N-t rmin s of β-arrestin2 (β-Arr). Upon activation by a c mokine
agonist, YFP-β-arrestin2 is recruited to the receptor, bringing the YFP and RLuc8 into close proximity and enabling the
resonance energy transfer after addition of the RLuc8 substrate coelenterazine h (coel). (b–d) Chemokine-induced β-arrestin
recruitment at (b) CCR4, (c) CCR7, and (d) CCR10. A dashed line of best fit is shown in the case that the signal does
not reach saturation. The presented data are mean ± SEM of at least three independent experiments, each performed
in triplicate.
For β-arrestin recruitment to CCR4, CCL22 stimulated a 3.5-fold higher maximal
response (Emax) than CCL17 (Figure 1b and Table 1). CCL22 also appeared to have higher
potency than CCL17 (pEC50 values of 8.1 ± 0.1 and 7.3 ± 0.3, respectively), although this
was not significant.
At CCR7, both CCL19 and CCL21 stimulated robust β-arrestin recruitment responses.
However, the potency was approximately 20-fold higher for CCL19 (pEC50 values of
7.9 ± 0.1 and 6.7± 0.1, respectively, assuming the same Emax value) and the CCL21 response
was not saturated at the highest concentration tested (Figure 1c and Table 1).
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Table 1. Potencies and maximal effects of cognate chemokines at CCR4, CCR7 and CCR10 1.
Receptor Assay Ligand
Potency
pEC50 ± SE 1
(EC50 in nM)
Maximal Effect (%)
Emax ± SE 1
CCR4 β-arrestin recruitment CCL17 7.31 ± 0.32 (48) 28 ± 6 **
CCL22 8.11 ± 0.10 (8) 100
G protein activation CCL17 ND ND
CCL22 ND ND
cAMP inhibition CCL17 ND ND
CCL22 ND ND
CCR7 β-arrestin recruitment CCL19 7.93 ± 0.06 (12) 100
CCL21 6.45 ± 0.03 (352) *** 100 (2)
G protein activation CCL19 8.71 ± 0.09 (2) 100
CCL21 7.54 ± 0.05 (29) *** 103 ± 3
cAMP inhibition CCL19 8.81 ± 0.12 (2) 100
CCL21 7.84± 0.16 (14) * 99 ± 6
CCR10 β-arrestin recruitment CCL27 7.01 ± 0.06 (97) 100
CCL28(1-108) ND ND
CCL28(4-108) ND 82 (3)
G protein activation CCL27 7.66 ± 0.05 (22) 100
CCL28(1-108) ND ND
CCL28(4-108) 6.92 ± 0.14 (121) 80 (3)
cAMP inhibition CCL27 7.27 ± 0.10 (54) 100
CCL28(1-108) ND ND
CCL28(4-108) 6.82 ± 0.23 (152) 64 (3)
NFAT Ca2+ reporter CCL27 8.24 ± 0.12 (6) 100
CCL28(1-108) ND ND
CCL28(4-108) 7.18 ± 0.10 (65) ** 106 ± 8
1 pEC50 values are the negative log of EC50, in molar units. The corresponding EC50 values (in nM) are shown in parentheses. Emax
values are relative to the reference ligand (CCL22, CCL19, or CCL27 at CCR4, CCR7, or CCR10, respectively). ND, not determinable from
the experimental data (see Figures 1–3). Data are mean ± SEM of at least three independent experiments, performed each in triplicate.
* p < 0.05, ** p < 0.01, *** p < 0.001, relative to the reference ligand at the same receptor. Statistical analysis was performed using one-way
ANOVA with Holm-Sidak’s multiple-comparison. 2 This Emax value was constrained to be the same as that of the reference ligand; the
corresponding pEC50 value is influenced by this assumption. 3 These Emax values listed are the maximum signals observed as the curves
did not reach saturation.
At CCR10, CCL27 exhibited robust β-arrestin recruitment (Figure 1d and Table 1).
We also tested the two commercially available forms of CCL28. Like other chemokines,
CCL28 is initially expressed with an N-terminal signal peptide, which is then proteolyti-
cally removed to yield the mature chemokine. Due to the ambiguity of predicting signal
peptide cleavage sites, CCL28 is available from different suppliers as the “full-length” form,
CCL28(1-108), or a form truncated by three N-terminal residues, CCL28(4-108). We ob-
served that CCL28(1-108) does not significantly stimulate β-arrestin recruitment at CCR10,
whereas the shorter form, CCL28(4-108), gave rise to robust, concentration-dependent
β-arrestin recruitment (Figure 1d and Table 1). However, since the CCL28(4-108) response
was not saturated at the highest concentration tested, we cannot determine whether its
potency or maximal response is significantly different from that of CCL27.
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Figure 2. Chemokine ligands differentially stimulate G protein activation via CCR4, CCR7 and CCR10. (a) The principle of
the BRET-based G-protein recruitment assay. RLuc8 is fused a the C-termi us tail of GRK3 (GRKct), which is localized to
the plasma membrane, and the YFP varia t Venus is tagged at the Gβ1γ2 dimer. Upon activation of a chemokine receptor,
the activity of the trimeric G protein complex (Gαi2 was overexpressed in this assay) can be detected as the dissociation of
Gαi and Gβγ; the latter binds to the GRK3 C-terminal tail, bringing the YFP and RLuc8 into close proximity and enabling
resonance energy transfer after addition of coelenterazine h (coel). (b–d) Chemokine-induced G-protein activation at (b)
CCR4 (c) CCR7, and (d) CCR10. A dashed line of best fit is shown in the case that the signal does not reach saturation. The
presented data are mean ± SEM of at least three independent experiments, each performed in triplicate.
2.2. Cognate Chemokines Stimulate G Protein-Mediated Signaling at CCR7 and CCR10 But Not
at CCR4
Upo binding their cognate ligands, most chemokine receptors undergo conforma-
tional changes that result in dissociation of the Gα subunit from the Gβγ subunit of
heterotrimeric G proteins and downstream suppression of cAMP synthesis catalysed by
adenylyl cyclase. For real-time measurement of these processes, we used a FlpIn-CHO cell
line stably transfected to express the receptor of interest and then transiently transfected
with BRET biosensors to report on G protein activation by the receptor (Figure 2a) or
inhibition of forskolin-induced cAMP synthesis (cAMP inhibition, Figure 3a).
In CCR7-expressing cells, CCL19 and CCL21 both stimulated robust responses in the
assays of G protein activation (Figure 2c and Table 1) and cAMP inhibition (Figure 3c and
Table 1). In these assays, both ligands induced similar maximal responses, but CCL19 was
more potent by ~15-fold for G protein activation and ~9-fold for cAMP inhibition. This is
similar to the relative effects of these ligands in β-arrestin recruitment at CCR7 (Figure 1c).
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YFP variant Venus. The conformation of Epac1, within CAMYEL, changes upon binding cAMP and this is used to monitor
cellular levels of cAMP by the change of BRET signals. (b–d) Chemokine-induced inhibition of cAMP production via (b)
CCR4 (c) CCR7 (d) CCR10. A dashed line of best fit is shown in the case that the signal does not reach saturation. The
presented data are mean ± SEM of at least three independent experiments, each performed in triplicate.
At CCR10, CCL27 and CCL18(4-108) both exhibited robust G protein activation
(Figure 2d and Table 1) and cAMP inhibition (Figure 3d and Table 1). Again, the CCL18(4-
108) signals were not saturated at the highest concentrations tested, precluding a rigorous
comparison of potencies, although CCL18(4-108) appears to be less potent than CCL27
in this assay. Similar to our observations in the β-arrestin recruitment assay (above), we
found that CCL28(1-108) stimulates only very weak G protein activation and cAMP inhibi-
tion. Thus, removing the first three amino acids of CCL28 substantially increases both the
potency and efficacy (maximum signal) of CCR10 activation in all three signalling readouts.
In stark contrast to the results for CCR7 and CCR10, both cognate chemokines of CCR4
failed to stimulate significant responses in assays of either G protein activation (Figure 2b
and Table 1) or cAMP inhibition (Figure 3b and Table 1). To ensure that this was not due to
lack of receptor expression, we took advantage of the N-terminal cMyc-tag on all receptors
used in this study to determine their expression levels by ELISA (Table 2). Relative cell
surface expression levels of CCR4, CCR7 and CCR10 in the stable FlpIn-CHO cell lines
used for G protein activation and cAMP inhibition assays were 1:2:30. Although, the FlpIn-
CHO-CCR4 cell line has the lowest receptor expression level among the cell lines used here,
the level was well above background and only ~2-fold lower than the CCR7 expression
level. This slightly lower receptor expression is unlikely to account for the complete lack of
G protein-mediated signalling observed. Nevertheless, to investigate this, we constructed
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a naturally occurring CCR4 that is truncated after residue Y331 (CCR4∆C29 [23]. This
mutant has been reported to display higher cell surface expression and gain of function in
a chemotaxis assay [24,25]. As expected, FlpInCHO cells stably expressed N-terminally
cMyc-tagged CCR4∆C29 at a level 25-fold higher than full-length CCR4, as assessed by
ELISA (Table 2). Despite its higher cell surface expression, CCR4∆C29 was not responsive
to up to 100 nM CCL17 or CCL22 in either G protein activation or cAMP inhibition assays
(data not shown). We therefore conclude that, when expressed in CHO cells, CCR4 is
capable of signalling via β-arrestin but not via G proteins.
Table 2. Expression levels (%) of chemokine receptors CCR4, CCR7 and CCR10 in CHO cells 1.
Receptor Normalized Expression Level
CCR4∆C29 CCR4 1004.2 ± 1.2
CCR7 7.9 ± 2.0
CCR10 120 ± 24
1 Cell surface expression levels of cMyc-tagged chemokine receptors in stably transfected FlpIn-CHO cells were
determined by cMyc ELISA. Reported levels (mean ± SEM, n ≥ 3) are arbitrarily normalized as percentage to the
corresponding level of C-terminally truncated (29 amino acid residues) CCR4 mutant (CCR4∆C29), determined
in parallel.
We also evaluated the signalling of CCR4, CCR7 and CCR10 using a reporter gene
assay for Nuclear Factor of Activated T Cells (NFAT), which is activated as a consequence
of increased cytosolic Ca2+ concentrations (Figure 4a). For this we co-transfected the cells to
express Gα15, which has previously been shown to couple to a variety of GPCRs originally
coupled to Gαs or Gαi, along with the NFAT reporter gene construct [26]. Treatment of the
CCR10-expressing cells with CCL27 or CCL18(4-108) yielded robust responses (Figure 4b
and Table 1), although the CCL27 response was approximately 10-fold more potent than
that of CCL28(4-108) (pEC50 values of 8.24 ± 0.12 and 7.18 ± 0.10, respectively, assuming
the same maximal effect). Once again, CCL28(1-108) stimulated only a weak response at
the highest concentrations tested. Moreover, treatment of the CCR4- or CCR7-expressing
cells with the cognate chemokines of these receptors did not yield any significant response
above background in the NFAT reporter assay (data not shown).
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Figure 4. Activation of CCR10 stimulates intracellular Ca2+ mobilization. (a) The principle of the NFAT activation assay.
Activation of a chemokine receptor leads to phospholipase C (PLC) activation via the transiently expressed Gα15, giving
rise to downstream release of Ca2+ from the endoplasmic reticulum (ER). Binding of Ca2+ to calmodulin (CaM) then
enables activation of the protein phosphatase calcineurin (Caln), which catalyzes dephosphorylation of NFAT, enabling
its translocation into the nucleus and transcription of the reporter firefly luciferase gene from an NFAT-sensitive reporter
construct. (b) Chemokine-induced NFAT activation via CCR10. The presented data are mean ± SEM of at least three
independent experiments, each performed in triplicate.
Finally, we quantified biased agonism at CCR7 and CCR10 using the Black and Leff
operational model [27,28]; this was not possible for CCR4 due to the lack of G protein-
mediated signaling. None of the possible comparisons provided significant evidence
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of biased agonism between ligands and pathways mediated by either CCR7 or CCR10
(data not shown). Indeed, this result is consistent with the observation that the relative
potencies and efficacies of the different ligands at each receptor are similar, irrespective of
the signaling readout.
3. Discussion
We have presented a systematic analysis of chemokine signaling at the chemokine
receptors CCR4, CCR7 and CCR10. We have shown that, in the same expression system,
the three receptors mediate different arrays of signaling outcomes. CCR10 was observed
to mediate G protein activation, leading to both cAMP inhibition (via Gαi/o) and Ca2+
mobilization (via overexpressed Gα15), as well as mediating β-arrestin recruitment. CCR7
could mediate the same downstream outcomes as CCR10 with the exception of Ca2+
mobilization. In contrast, stimulation of CCR4 did not give rise to any G protein-mediated
signaling but clearly induced β-arrestin recruitment.
At each receptor, the ligands tested were not equivalent in the signaling responses
that they induced. However, the nature of these differences varied amongst the receptors
and ligands studied. The CCR4 ligands differed primarily in their maximal effect (efficacy)
of β-arrestin recruitment. The CCR7 ligands differed primarily in their potency in all
signaling outcomes tested. The CCR10 ligand CCL27 gave robust signals in all assays,
whereas CCL28(1-108) gave very weak signals, although the truncated form, CCL28(4-108),
gave similar responses to CCL27, with slightly lower potency in most assays. Moreover,
in some cases, the ligand-selective effects contrast with those previously reported for the
same receptor and ligands. Below, we discuss the details of these effects for each receptor
and attempt to rationalize any inconsistencies between studies.
Our observations that, in all assays, CCL19 displayed higher potency but similar effi-
cacy compared to CCL21, are consistent with previous observations. Early studies reported
that, when compared at the same concentration (100 nM), CCL19 was more effective than
CCL21 in inducing internalization of CCR7 [19,20]. Similarly, Zidar et al. reported that, in
transfected human embryonic kidney (HEK293) cells, CCL19 promoted stronger β-arrestin
recruitment than CCL21, although they also found that the two ligands stimulated equiva-
lent G protein-mediated responses [7]. Initially, this appeared to suggest biased agonism by
these ligands. Indeed, the same authors found that receptor phosphorylation was mediated
by different sets of GRKs, which suggests alternative receptor conformations were favored
by the two ligands. However, the signaling experiments of Zidar et al. used a single concen-
tration (100 nM) of each ligand. Our data clearly show that, at this concentration, CCL19
elicits much stronger β-arrestin recruitment than CCL21 (Figure 1c) but both ligands elicit
maximal responses in G protein-mediated readouts (Figures 2c and 3c). This results from
the β-arrestin signal being essentially unamplified, whereas the G protein-mediated signals
are somewhat amplified, causing a left-shift of the concentration-response curves [10].
Additionally, consistent with our data, Corbisier et al. found that CCL19 was more potent
than CCL21 in both G protein activation and β-arrestin recruitment (in HEK293 cells),
with no significant bias between these ligands and pathways [9]. Two recent studies by
Rosenkilde and colleagues have identified features of both the chemokines and CCR7
that contribute to the higher potency of CCL19 [8,21]. In particular, the higher potency of
CCL19 was suggested to result from differential interactions of the core domains of the two
chemokines with extracellular loop 2 of the receptor [8].
Our CCR10 activation data show that “truncated” CCL28(4-108) robustly activates
CCR10, whereas “full-length” CCL28(1-108) has minimal activity in all four signaling
readouts tested (Figures 1d, 2d, 3d and 4b). This raises the question of which form(s) of
CCL28 is/are biologically relevant. To the best of our knowledge, there are no available
data reporting on the naturally occurring N-terminal sequence or molecular mass of
CCL28. However, the SignalP program [29] predicts cleavage of the CCL28 precursor
at the sequence SEA-ILP (‘-‘ indicates the cleavage site) to yield CCL28(4-108) with 68%
probability, compared with cleavage at the sequence LHA-SEA to yield CCL28(1-108) with
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only 21% probability. Based on this prediction and our activity data, we propose that the
active biological form is CCL28(4-108), whose N-terminal sequence, up to CC motif, is
ILPIASSCC, and that future physiological studies of CCL28 activity mediated by CCR10
should focus on the shorter form of CCL28. We note, however, that CCL28 has also been
reported to activate the receptor CCR3 [30] and that the form(s) of CCL28 active at this
receptor remain(s) to be determined.
Unlike the CCR7 observations, our CCR10 activation data differ substantially from a
previous report. Rajagopal et al. reported that CCL27 stimulated both G protein-mediated
and β-arrestin-recruitment via CCR10, whereas CCL28 stimulated only G protein-mediated
signaling; they reported using commercial CCL28(4-108) [4]. This appeared to be a clear
example of biased agonism and raised the possibility that differential signaling plays a
part in the selectivity of CCL27 and CCL28 for CCR10-expressing T and B lymphocytes,
respectively. Our data confirm that CCL27 stimulates both signaling pathways, but differ
from the previous report in that we found that CCL28(4-108) also stimulates both G protein-
mediated and β-arrestin recruitment via CCR10 (Figures 1d, 2d and 3b), with no evidence of
biased agonism between these pathways. We note that the differences in potency observed
for CCL27 in the different assays are as expected, due to the different levels of signal
amplification/effector coupling in these assays.
On the other hand, we observed a clear difference between the potencies of CCL27 and
CCL28(4-108) in the Ca2+-sensitive NFAT reporter assay, suggesting subtle bias between
different G protein mediated pathways. We note that this apparent bias may be exaggerated
because the NFAT assay is highly amplified in comparison to the other assays used here.
Previous studies have found differences in the responses of CCR4-expressing cells
to its two cognate ligands. Activation with CCL22, but not with CCL17, has been re-
ported to desensitize CCR4-expressing murine pre-B cells to subsequent activation by
either chemokine [15] and induce rapid internalization of CCR4 in human Th2 cells [16].
Consistent with these differences, Ajram et al. observed, using the proprietary DiscoverX®
cell line, that CCL22, but not CCL17, induced β-arrestin recruitment to CCR4, at chemokine
concentrations up to 100 nM [6]. We found that CCL17 does induce β-arrestin recruitment
to CCR4 expressed in CHO cells, albeit relatively weakly, at concentrations of 100 nM or
higher (Figure 1b). This is in agreement with Viney et al., who reported that 100 nM CCL17
induced significant internalization of CCR4 in the human T cell line Hut78 [17]. These
relatively subtle differences in responses to CCL17 may simply reflect the variety of cell
types, receptor expression levels and assay formats used in these different studies.
However, there are more substantial differences in the G protein-mediated responses
to CCR4 activation observed across different studies. Imai et al. [15] showed robust Ca2+
mobilization in response to both CCL17 and CCL22 in CCR4-transfected murine pre-B
(L1.2) cells. They also observed chemotaxis of L1.2-CCR4 and Hut78 cells, with CCL22
inducing higher maximal response than CCL17. GPCR-mediated Ca2+ mobilization and
chemotaxis are generally known to be mediated by G protein signaling, although Lin et al.
demonstrated that β-arrestin 2 also plays a partial but important role in CCR4-mediated
chemotaxis of murine Th2 cells [31]. Subsequently, Viney et al. [17] reported that CCL17 and
CCL22 displayed equal potency and efficacy in assays of both Ca2+ mobilization (in Th2
cells) and chemotaxis (in Hut78 cells or L1.2-CCR4 cells). While CCR4-mediated G protein
signaling is apparent in the abovementioned leukocyte cell lines, our results suggest that
CCR4 expressed in CHO cells is unable to transmit signal via G proteins. The differences
in G protein-mediated responses could be due to expression of different isoforms of G
proteins in different cell types. Furthermore, CCR4-mediated G protein activity has been
detected in isolated membrane preparations from CCR4-expressing CHO cells, using a
[35S]GTPγS binding assay [6,32]. This suggests that CHO cells may express soluble factors
that suppress G protein signaling by CCR4 in intact cells.
Irrespective of the mechanisms underlying the selective signaling of CCR4 via β-
arrestin in CHO cells, our results show that, in certain cellular contexts, CCR4 is capable
of supporting β-arrestin recruitment but not G protein-mediated signaling. This effect is
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reminiscent of atypical chemokine receptors, which lack the DRY sequence motif (which
is present in CCR4) and therefore do not couple efficiently to G proteins but still support
β-arrestin-mediated events, leading to internalization and scavenging of chemokine lig-
ands [33]. Such scavenging behavior has also been reported for other classical chemokine
receptors, such as CCR1 and CCR2 [34–36]. Therefore, we now suggest that CCR4 should be
viewed as a versatile receptor whose G protein-mediated (pro-chemotactic) and β-arrestin-
mediated (scavenging) functions vary with different cellular contexts and could potentially
be regulated by such factors as intracellular binding partners, membrane environment, and
post-translational modifications.
Finally, it is noteworthy that stimulation of some chemokine receptors, including both
CCR4 and CCR7, has previously been reported to induce not only recruitment of β-arrestins
leading to receptor internalization, but also downstream signaling via β-arrestin-mediated
pathways. Specifically, Lin et al. showed, by genetic deletion of β-arrestin2, that CCL22-
induced, CCR4-mediated chemotaxis of Th2 cells was dependent, in part, on a signaling
pathway mediated by β-arrestin2 [31]. In addition, Zidar et al. showed, using β-arrestin
siRNA in HEK293 cells expressing CCR7, that optimal pERK signaling was dependent on
β-arrestin2 expression but opposed by β-arrestin1 expression [7]. The current study did
not investigate β-arrestin-mediated signaling per se.
In summary, our systematic study of G protein signaling and β-arrestin recruitment by
cognate chemokines at CCR4, CCR7 and CCR10 highlights significant differences between
the intracellular signals elicited. At CCR7, both CCL19 and CCL21 stimulate both G protein-
mediated and β-arrestin-signals, with CCL19 consistently displaying higher potency. At
CCR10, CCL27 and CCL28(4-108), but not CCL28(1-108), stimulate G protein-mediated
and β-arrestin-signals, suggesting that CCL28(4-108) is the biologically active form of
this chemokine. Finally, at CCR4, both CCL17 and CCL22 selectively activate β-arrestin-
mediated pathways, with CCL22 stimulating a substantially stronger signal, suggesting
that CCR4 has the potential to act as a scavenger receptor. Comparisons of our results with
previous studies further indicate that differential agonism at these receptors may be highly
dependent on the cellular context.
4. Materials and Methods
4.1. Materials
FlpInCHO cells were purchased from Thermo Fisher Scientific. Dulbecco’s modified
Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, hygromycin B,
and D-luciferin were obtained from Life Technologies (Carlsbad, CA, USA). Coelenterazine
h was purchased from Prolume (Pinetop, AZ, USA). Enzymes and other materials for
molecular cloning were sourced from New England Biolabs (Ipswich, MA, USA). Linear
25 kDa polyethyleneimine (PEI) was from Polysciences (Warrington, PA, USA). The human
chemokines CCL17, CCL19, CCL21, CCL22, CCL27 and CCL28 (1-108) were supplied by
Peprotech (Cranbury, NJ, USA) and human CCL28(4-108) was from BioLegend (San Diego,
CA, USA). White 96-well CulturPlates were purchased from PerkinElmer (Boston, MA,
USA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
4.2. Cell Lines Stably Expressing Human CCR4, CCR7, and CCR10
The cDNAs encoding the human CCR4, CCR7, and CCR10 were obtained from
the cDNA Resource Center (www.cDNA.org). A nucleotide sequence encoding C-myc
peptide (MEQKLISEEDL) followed by GGATCCGGA (encoding peptide sequence GSG,
and including a BamHI site) was added to the 5′ end of the cDNAs and cloned into a
modified pcDNA5/FRT/TO vector (the CMV promoter of the original vector is replaced
with the EF1α promoter from pEF4).
FlpInCHO cells were maintained in DMEM supplemented with 5% FBS and 100 u/mL
penicillin and 100 µg/mL streptomycin. For stable transfection, the transfection mixture
(4.5 µg pOG44, 0.5 µg plasmid containing the receptor construct, and 30 µg PEI in 0.5 mL
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150 mM NaCl) was added into a 10-cm dish containing four million adherent cells. One
day after transfection, the cells were diluted and selected with 200 µg/mL hygromycin B.
4.3. β-Arrestin Recruitment Assay
The DNAs encoding Renilla luciferase variant 8 (RLuc8) tagged at the C-termini
of CCR4, CCR7, and CCR10 were constructed by PCR amplifying the C-myc-tagged
chemokine receptor cDNAs mentioned above and cloned into a pcDNA3.1-derived plasmid
containing the gene encoding Rluc8 [37]. The DNA encoding yellow fluorescent protein
(YFP) tagged at the N-terminus of the rat β-arrestin2 [37] was obtained from Prof. Kevin
Pfleger.
The C-myc-CCR4-RLuc8, C-myc-CCR7-RLuc8, and C-myc-CCR10-RLuc8 genes were
transiently co-expressed with YFP-β-arrestin2 in FlpInCHO cells by transfection (4.5 µg
receptor-Rluc DNA + 0.5 µg YFP-β-arrestin2 DNA in a 10-cm dish containing four million
cells). One day after transfection, the cells were transferred into a white 96-well plate
at a density of 50,000 cells/well in 100 µL medium and incubated overnight. The cells
were stimulated in Hank’s balanced salt solution (HBSS) in the presence of chemokine
at the indicated concentrations and 5 µM coelenterazine-h, with a total assay volume of
80 µL. The BRET signals were measured at 10 min after stimulation, using a PHERAstar
microplate reader (BMG Labtech, Ortenberg, Germany) to detect the fluorescence at the
wavelengths 450–500 nm and 515–560 nm.
4.4. G Protein Activation Assay
FlpInCHO cells stably expressing the chemokine receptors were transiently transfected
to express the biosensors for G-protein activation, including Gαi2, Gβ1-venus (containing
amino acid 156–239 of venus), Gγ2-venus (containing amino acid 1–155 of venus), and
mas-GRK3ct-RLuc8 [38]. One day after transfection, the cells were transferred into a
96-well plate, stimulated and BRET was detected as described above for the β-arrestin
recruitment assay.
4.5. cAMP Inhibition Assay
FlpInCHO cells stably expressing the chemokine receptors were transiently transfected
to express the biosensors for cAMP, called CAMYEL [39]. One day after transfection, the
cells were transferred into a 96-well plate, stimulated and BRET was detected as described
above for the β-arrestin recruitment assay.
4.6. NFAT Activation Assay
FlpInCHO cells stably expressing the chemokine receptors were transiently trans-
fected to express Gα15 (obtained from the cDNA Resource Center) and the NFAT-firefly
luciferase reporter gene. The transfer of the transfected cells into white 96-well plates
performed the same way as described above. The cells were stimulated for six hours with
several concentrations of chemokines, diluted in DMEM at a total volume of 100 µL/well.
The medium was discarded and firefly luciferase activity was measured in 25 µL luciferase
reagent (0.8 mM ATP, 230 µg/mL D-luciferin, 18 mM MgCl2, 77 µM Na2H2P2O7, 24 mM
Tris–H3PO4 (pH 7.8), 24% (v/v) glycerol, 1.6% (v/v) Triton X-100, and 527 µM dithiothre-
itol) using a PHERAstar microplate reader (BMG Labtech, Ortenberg, Germany) at 15 min
after the addition of the reagent.
4.7. Enzyme-Linked Immunosorbent Assay (ELISA)
The FlpInCHO cells stably expressing the chemokine receptors were transferred to a
48-well plate (100,000 cells/well in growth medium) and incubated overnight. The cells
were washed, fixed with 4% formaldehyde (in phosphate-buffered saline, PBS) for 30 min,
incubated with blocking buffer (PBS in the presence of 1% bovine serum albumin (BSA))
for 1 h, and then exposed to 400 ng/mL monoclonal 9E10 anti-Myc (CSIRO, Melbourne,
Australia) for 2 h. The cells were washed two times before treated for 1 h with HRP-
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conjugated rabbit anti-mouse antibody (Sigma Aldrich) that was 1000-fold diluted in PBS
supplemented with 1% BSA. After washing out the secondary antibody, the enzymatic
reaction was performed using SigmaFastTM OPD (Sigma Aldrich) and terminated with 3 M
HCl. The A492 was measured in a PHERAstar microplate reader (BMG Labtech, Ortenberg,
Germany).
4.8. Data Analysis and Statistics
The BRET signal presented in this manuscript is defined the ratio of fluorescence
signals measured at 515–560 nm to those measured at 515–560 nm. For data normalization,
0% is defined as the activity of a receptor in the absence of any chemokine and 100% is
the maximal effect (Emax) of CCL22, CCL19, or CCL27 at the relevant receptor (CCR4,
CCR7, or CCR10, respectively), with the exception for CCR4 in G protein activation and
cAMP inhibition assays. For these latter cases, 0% is defined as the activity of a receptor
in the absence of any chemokine and the maximal effect (Emax) of CCL27 at CCR7 is used
as a surrogate 100%. The concentration vs. response data were plotted and analyzed
with the standard single slope dose–response mathematical model of GraphPad Prism 8.0
(GraphPad Software, CA, USA).
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Abbreviations
ANOVA analysis of variance
BRET bioluminescence resonance energy transfer
BSA bovine serum albumin
cAMP 3’,5’-cyclic adenosine monophosphate
CCL C-C motif chemokine ligand
CCR C-C motif chemokine receptor
CHO Chinese hamster ovary
CXCR C-X-C motif chemokine receptor
DC dendritic cell
DMEM Dulbecco’s modified Eagle’s medium
Emax maximal response
ELISA enzyme-linked immunosorbent assay
GPCR G protein-coupled receptor
pEC50 log10(EC50) where EC50 is the concentration (in molar) required for 50% activation




RLuc8 Renilla luciferase 8
Th2 T helper type 2
YFP yellow fluorescent protein
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